Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
Real-time Estimate Quote. Real-time Estimate Cboe BZX - 12/07 09:54:39 am
272.995 USD   +2.89%
07:45aMarketScreener's World Press Review - December 7, 2021
07:16aEU agencies endorse mix-and-match of COVID-19 vaccines
RE
06:46aREFILE-EU health bodies recommend mix-and-match of COVID-19 vaccines
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna : U.S. FDA delays decision on Moderna's COVID-19 vaccine for adolescents - WSJ

10/15/2021 | 01:11pm EST

Oct 15 (Reuters) - The U.S. health regulator is delaying its decision on authorizing Moderna Inc's COVID-19 vaccine for adolescents to check if the shot could increase the risk of a rare inflammatory heart condition, the Wall Street Journal reported on Friday.

The U.S. Food and Drug Administration (FDA) has been inspecting the risk of the condition, myocarditis, among younger men vaccinated with Moderna's shot, especially versus Pfizer's vaccine, after certain Nordic countries limited use of the shot, the report https://on.wsj.com/3p3P5Zp said, citing people familiar with the matter.

The agency has not yet determined whether there is heightened risk, and the delay could be several weeks, though the timing was unclear, the report said.

In June, Moderna filed for U.S. authorization of its vaccine among adolescents aged 12 through 17. The FDA authorized rival Pfizer's vaccine for use in children as young as 12 in May.

The U.S. FDA's review of Moderna's application is ongoing, an FDA spokesperson told Reuters, adding that while the agency cannot predict how long the process may take, it is evaluating the data as expeditiously as possible.

Europe's drug regulator found in July that such inflammatory conditions could occur in very rare cases following vaccination with Moderna's vaccine or Pfizer/BioNTech's shot, more often in younger men after the second dose.

However, the regulator stressed that the benefits of the shots outweighed any risks.

Earlier this month, Finland, Sweden and Denmark paused the use of Moderna's shot for younger males due to reports of myocarditis, though the Danish Health Agency later said the vaccine was available to under-18s.

Moderna's two-shot vaccine has U.S. authorization for emergency use in people aged 18 and above.

The FDA in June added a warning https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-adds-warning-about-rare-heart-inflammation-pfizer-moderna-covid-vaccines-2021-06-26 to the literature accompanying Pfizer/BioNTech and Moderna COVID-19 shots to indicate the rare risk of heart inflammation.

(Reporting by Amruta Khandekar; Editing by Devika Syamnath and Mjau Samuel)


ę Reuters 2021
All news about MODERNA, INC.
07:45aMarketScreener's World Press Review - December 7, 2021
07:16aEU agencies endorse mix-and-match of COVID-19 vaccines
RE
06:46aREFILE-EU health bodies recommend mix-and-match of COVID-19 vaccines
RE
06:23aCowen Starts Moderna at Market Perform With $250 Price Target
MT
12/06AstraZeneca, Pfizer-BioNTech's COVID-19 Jabs Work Well With Moderna Shot, UK Study Says
MT
12/06Mixing Pfizer, AstraZ COVID-19 shots with Moderna gives better immune response -UK stud..
RE
12/06Health Care Up As Moderna Slides -- Health Care Roundup
DJ
12/06Wall Street regains some ground with help from easing virus fears
RE
12/06US Indices Rebound on Indications Omicron Less Severe Than Previously Anticipated; Trea..
MT
12/06Delta, Kohl's rise; Moderna, AST SpaceMobile fall
AQ
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2021 17 505 M - -
Net income 2021 11 217 M - -
Net cash 2021 12 344 M - -
P/E ratio 2021 10,1x
Yield 2021 -
Capitalization 108 B 108 B -
EV / Sales 2021 5,44x
EV / Sales 2022 4,08x
Nbr of Employees 1 300
Free-Float 90,5%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 19
Last Close Price 265,33 $
Average target price 271,13 $
Spread / Average Target 2,18%
EPS Revisions
Managers and Directors
StÚphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.153.98%107 578
LONZA GROUP AG25.98%56 683
IQVIA HOLDINGS INC.46.84%50 262
SEAGEN INC.-16.63%26 699
CELLTRION, INC.-42.48%23 888
ICON PUBLIC LIMITED COMPANY36.39%21 647